Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.

Front Endocrinol (Lausanne) · 2023 · PMC10534984 · PMID 37780624

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Conversely, the reduction in VAT, although documented at both T3 and T6 compared with T0, did not reach statistical significance (see Table 4 and Figure 5 ) Most importantly, the significant weight loss in patients did not lead to a simultaneous decrease in Fat-Free Mass (FFM) and indexed FFM (FFMI) ( Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.